Zacks: Analysts Expect G1 Therapeutics, Inc. (NASDAQ:GTHX) Will Announce Earnings of -$0.99 Per Share

Brokerages expect that G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) will announce earnings of ($0.99) per share for the current quarter, Zacks reports. Five analysts have made estimates for G1 Therapeutics’ earnings, with estimates ranging from ($1.07) to ($0.94). G1 Therapeutics posted earnings of ($0.65) per share during the same quarter last year, which indicates a negative year over year growth rate of 52.3%. The firm is expected to issue its next quarterly earnings results before the market opens on Monday, January 1st.

On average, analysts expect that G1 Therapeutics will report full year earnings of ($3.75) per share for the current financial year, with EPS estimates ranging from ($4.16) to ($3.42). For the next year, analysts forecast that the firm will report earnings of ($2.97) per share, with EPS estimates ranging from ($3.90) to ($2.55). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that that provide coverage for G1 Therapeutics.

G1 Therapeutics (NASDAQ:GTHX – Get Rating) last issued its quarterly earnings results on Wednesday, February 23rd. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.09. The business had revenue of $5.80 million during the quarter, compared to analyst estimates of $5.45 million. G1 Therapeutics had a negative net margin of 471.32% and a negative return on equity of 76.03%. During the same quarter in the previous year, the firm earned ($0.67) earnings per share.

A number of brokerages recently issued reports on GTHX. Needham & Company LLC restated a “buy” rating and issued a $44.00 price target on shares of G1 Therapeutics in a research note on Thursday, April 14th. Zacks Investment Research lowered shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $37.00.

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in G1 Therapeutics by 2.1% during the fourth quarter. BlackRock Inc. now owns 3,310,212 shares of the company’s stock valued at $33,799,000 after purchasing an additional 68,127 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in shares of G1 Therapeutics by 30.5% during the fourth quarter. Fisher Asset Management LLC now owns 2,268,074 shares of the company’s stock valued at $23,157,000 after acquiring an additional 529,863 shares during the period. Lombard Odier Asset Management Switzerland SA boosted its holdings in shares of G1 Therapeutics by 9.2% during the fourth quarter. Lombard Odier Asset Management Switzerland SA now owns 1,049,947 shares of the company’s stock valued at $10,720,000 after acquiring an additional 88,808 shares during the period. BioImpact Capital LLC boosted its holdings in shares of G1 Therapeutics by 5.9% during the third quarter. BioImpact Capital LLC now owns 860,502 shares of the company’s stock valued at $11,548,000 after acquiring an additional 47,708 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of G1 Therapeutics by 11.2% during the fourth quarter. Geode Capital Management LLC now owns 715,373 shares of the company’s stock valued at $7,303,000 after acquiring an additional 72,270 shares during the period. Hedge funds and other institutional investors own 63.73% of the company’s stock.

Shares of NASDAQ:GTHX opened at $5.43 on Friday. The company has a current ratio of 8.82, a quick ratio of 8.69 and a debt-to-equity ratio of 0.52. The company has a fifty day simple moving average of $8.29 and a 200 day simple moving average of $10.49. The firm has a market cap of $231.89 million, a PE ratio of -1.54 and a beta of 1.93. G1 Therapeutics has a 12-month low of $5.07 and a 12-month high of $24.12.

About G1 Therapeutics (Get Rating)

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.

Featured Articles